Parkinson's Advisory Committee: Nuplazid Review Will Test Targeted Endpoint
This article was originally published in The Pink Sheet Daily
Acadia's pimavanserin would be first treatment for psychosis related to Parkinson's, but it only succeeded after endpoint was refined in second Phase III trial.
You may also be interested in...
After meeting with FDA, Acadia announces it needs only one pivotal study for pimavanserin. The company has canceled a second study and expects to file at the end of 2014. Faster NDA pathway could mean launch a year earlier than expected.
If Biden administration wants to nominate the acting commissioner, Vacancies Reform Act would dictate the timing. Woodcock can still get the nod and remain head of the agency during the confirmation process, just as Andrew von Eschenbach retained his acting title following his nomination in 2006.
President Biden’s picks to fill two commissioner posts may shift dynamics on pharmaceutical industry enforcement. Rohit Chopra’s nomination to Consumer Financial Protection Bureau removes strong critic of pharma mergers.